Be SMART NIS, Moderate to Servere Asthma Patient Observation

This study has been completed.

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00514787

Purpose

Screen for moderate to severe asthma patients with suboptimal asthma control (as defined by GINA-Guidelines). Document current asthma control status. Re-evaluate asthma therapy and document new therapy if applicable.

Condition
Asthma

MedlinePlus related topics: Asthma

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective
Official Title:	Be SMART NIS, Moderate to Servere Asthma Patient Observation

Further study details as provided by AstraZeneca:

Estimated Enrollment:	900
Study Completion Date:	January 2008
Primary Completion Date:	January 2008 (Final data collection date for primary outcome measure)

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Moderate to severe asthma with suboptimal control

Exclusion Criteria:

Intermittent or mild asthma, patient with good asthma control

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00514787

Locations

Austria
Research Site
Vienna, Austria

Sponsors and Collaborators

AstraZeneca

Investigators

Study Chair:

Wolfgang Pohl, PHD

Executive Board OGP (Austria Society of Pneumology

More Information

Study ID Numbers:	NIS-RAT-SYM-2007/1
Study First Received:	August 9, 2007
Last Updated:	October 21, 2008
ClinicalTrials.gov Identifier:	NCT00514787
Health Authority:	Austria: Agency for Health and Food Safety

Keywords provided by AstraZeneca:

Asthma
NIS

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Respiratory Tract Diseases
Lung Diseases

Hypersensitivity, Immediate
Asthma
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Immune System Diseases
Bronchial Diseases

ClinicalTrials.gov processed this record on January 16, 2009